Are you ready to amplify your academic presence and connect with a global network of researchers? Join the Scholar Indexing Society and elevate your research to new heights!
Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
Article Number: SIS259306AI231222
23rd December, 2022
Author(s):
Christian J. Wiedermann, Klaus Eisendle
Abstract:
This article aims to highlight the positions of the Food and Drug Administration and the European Medicines
Agency regarding use and marketing of hydroxyethyl starch (HES) products, and how these have changed over
recent years. In 2013, warnings from both agencies advised against use of HES in critically ill patients, including
patients with sepsis, when several large randomized controlled trials on volume resuscitation in critical illness failed
to observe clinically beneficial effects of HES. In areas such as patient monitoring and requirements for further
clinical trials, the FDA and EMA are very much in agreement in their recommendations. However, EMA guidance is
generally more restrictive on HES usage compared to that from the FDA. Differences in data presented to
regulatory authorities, bias in study results and inherent weakness of meta-analyses used for drug surveillance
purposes, plus different risk-management approaches used by the two regulatory authorities, likely contribute to
different outcomes in their regulations concerning use of HES.